Windlas Biotech Limited (NSE:WINDLAS)

India · Delayed Price · Currency is INR

993.60

+5.40 (0.55%)

Aug 21, 2026, 3:29 PM IST

-2.89% (1Y)

Market Cap	20.50B -4.4%
Revenue (ttm)	9.42B +18.5%
Net Income	664.44M +1.9%
EPS	31.13 +1.2%
Shares Out	20.64M
PE Ratio	31.92
Forward PE	n/a
Dividend	6.30 (0.69%)
Ex-Dividend Date	Jul 16, 2026

Volume	173,115
Open	990.00
Previous Close	988.20
Day's Range	954.05 - 1,009.80
52-Week Range	697.40 - 1,045.45
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 10, 2026

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophiliz... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2001

Employees 1,385

Stock Exchange National Stock Exchange of India

Ticker Symbol WINDLAS

Full Company Profile

Financial Performance

In fiscal year 2026, Windlas Biotech's revenue was 9.04 billion, an increase of 18.98% compared to the previous year's 7.60 billion. Earnings were 664.56 million, an increase of 8.95%.

Financial Statements